Nuvalent (NUVL) Non-Current Assets (2021 - 2026)
Nuvalent (NUVL) reported Non-Current Assets of $23.2 million for Q1 2026, up 20.56% on a YoY basis from $19.3 million in Q1 2025, and up 14.46% quarter-over-quarter from $20.3 million in Q4 2025.
Nuvalent (NUVL) Non-Current Assets (2021 - 2026) Analysis & Trends
Nuvalent has reported Non-Current Assets for 6 years, with the latest figure at $23.2 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 20.56% year-over-year to $23.2 million; the trailing twelve-month figure through Mar 2026 stood at $87.4 million (up 87.08% YoY), and the FY2025 full-year result was $20.3 million, up 117.96% from the prior year.
- Non-Current Assets for Q1 2026 stood at $23.2 million, up from $20.3 million in the prior quarter.
- The five-year high for Non-Current Assets was $23.2 million in Q1 2026, with the low at $2.6 million in Q1 2022.
- Historically, Non-Current Assets has averaged $10.6 million across 5 years, with a median of $9.0 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets slipped 0.52% — and 2025, when it soared 150.08%.
- Nuvalent's Non-Current Assets stood at $4.5 million in 2022, then jumped by 31.96% to $5.9 million in 2023, then surged by 57.8% to $9.3 million in 2024, then surged by 117.96% to $20.3 million in 2025, then grew by 14.46% to $23.2 million in 2026.
- The last three Non-Current Assets figures came in at $23.2 million (Q1 2026), $20.3 million (Q4 2025), and $23.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 39.71 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | 23.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.21 Mn |
| Dec 31, 2025 | 20.28 Mn |
| Sep 30, 2025 | 22.97 Mn |
| Jun 30, 2025 | 20.93 Mn |
| Mar 31, 2025 | 19.25 Mn |
| Dec 31, 2024 | 9.30 Mn |
| Sep 30, 2024 | 9.18 Mn |
| Jun 30, 2024 | 8.97 Mn |
| Mar 31, 2024 | 8.97 Mn |
| Dec 31, 2023 | 5.90 Mn |
| Sep 30, 2023 | 5.31 Mn |
| Jun 30, 2023 | 4.96 Mn |
| Mar 31, 2023 | 4.70 Mn |
| Dec 31, 2022 | 4.47 Mn |
| Sep 30, 2022 | 4.31 Mn |
| Jun 30, 2022 | 4.20 Mn |
| Mar 31, 2022 | 2.57 Mn |
| Dec 31, 2021 | 3.20 Mn |
| Sep 30, 2021 | 2.83 Mn |
| Jun 30, 2021 | 4.22 Mn |